Abstract: Compositions for and methods of treating irritable bowel disease are provided. The compositions and methods employ MG53, which can be in the form of recombinant human MG53. The MG53 can be administered in a form to avoid or bypass gastric digestion or degradation. The composition can include a live MG53-expressing microbe, such as a probiotic composition that expresses MG53 in the gastrointestinal tract of a subject. An enteric release composition comprising MG53 is also provided.
Type:
Application
Filed:
May 10, 2022
Publication date:
September 1, 2022
Applicants:
OHIO STATE INNOVATION FOUNDATION, DAPING HOSPITAL, ARMY MEDICAL UNIVERSITY, Institute of Microbiology, Chinese Academy of Sciences
Abstract: Compositions for and methods of treating liver injury are provided. Said compositions comprise MG53 or express MG53. Said compositions can be used for treating chronic or acute injured liver tissue and can be administered systemically, locally, or both.
Type:
Application
Filed:
December 13, 2021
Publication date:
April 7, 2022
Applicants:
OHIO STATE INNOVATION FOUNDATION, DAPING HOSPITAL, ARMY MEDICAL UNIVERSITY
Inventors:
CHUNYU ZENG, Yu HAN, Jianjie MA, Tao TAN